Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular DegenerationThis study is designed for multi-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single and multiple intravitreal injection of IBI333 in subjects with neovascular age-related macular degeneration (nAMD).
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients...
Wet Macular DegenerationNeovascular Age-related Macular Degeneration1 moreThe goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.
Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related...
Neovascular Age-related Macular DegenerationPhase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of suprachoroidally administered CLS-AX 1.0 mg with a flexible dosing regimen in participants with neovascular age-related macular degeneration previously treated with intravitreal anti-vascular endothelial growth factor (VEGF) standard of care therapy. Only one eye will be chosen as the study eye.
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Neovascular Age-Related Macular DegenerationThis study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Exudative Macular DegenerationThe purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular DegenerationA 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
Neovascular Age-related Macular DegenerationDiabetic Macular Edema1 morePatients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion-Macular edema (RVO-ME).
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular...
Neovascular Age-related Macular DegenerationNeovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of blindness in patients over 65 years of age. The abnormal angiogenic process in nAMD is stimulated and modulated by vascular endothelial growth factor (VEGF). Treatment of nAMD requires frequent intravitreal (IVT) injections of VEGF inhibitors (anti-VEGF) administered every 4-16 weeks. ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product being developed for the treatment of nAMD and offers the potential for sustained intraocular expression of aflibercept following a single IVT injection. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked...
Neovascular Age-related Macular Degeneration (NVAMD)Diabetic Macular Edema (DME)EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE103 will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part two doses of EYE103 will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.
Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular...
Neovascular Age-related Macular DegenerationThis is a Phase 1 study, first-in-human (FIH), open label study to evaluate the safety, tolerability and identify the maximum tolerated dose (MTD) of PMC-403 and determine the recommended phase 2 dose (RP2D).